| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10036449 | HBV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS10050122 | HBV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS30085065 | HIV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20007380 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20007381 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20010779 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20035928 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20057329 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20021555 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20056904 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HRH1 |
|---|---|
| DrugBank ID | DB00283 |
| Drug Name | Clemastine |
| Target ID | BE0000442 |
| UniProt ID | P35367 |
| Regulation Type | antagonist |
| PubMed IDs | 11752352; 2890562; 6701456; 6387510; 1678430; 7513381; 4074605; 6449094; 1266718; 8930778 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Taniguchi K, Urakami M, Takanaka K: [Effects of antiallergic agents on polymorphonuclear leukocytes. The inhibition of arachidonic acid release and superoxide production]. Nihon Yakurigaku Zasshi. 1987 Aug;90(2):97-103.@@Hallberg T, Dohlsten M, Baldetorp B: Demonstration of histamine receptors on human platelets by flow cytometry. Scand J Haematol. 1984 Feb;32(2):113-8.@@Dorsch W, Hintschich C, Neuhauser J, Weber J: Sequential histamine inhalations cause increased bronchial histamine reactivity in guinea pigs: role of platelets, thromboxanes and prostacyclin. Naunyn Schmiedebergs Arch Pharmacol. 1984 Sep;327(2):148-55.@@Taniguchi K, Masuda Y, Takanaka K: Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils. J Pharmacobiodyn. 1991 Feb;14(2):87-93.@@Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4.@@Thomas RH, Browne PD, Kirby JD: The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin. Br J Clin Pharmacol. 1985 Oct;20(4):377-82.@@Thomson NC, Kerr JW: Effect of inhaled H1 and H2 receptor antagonist in normal and asthmatic subjects. Thorax. 1980 Jun;35(6):428-34.@@Hayashi H, Okajima M, Yamada K: Atrial T (Ta) loop in dogs with or without atrial injury. Am Heart J. 1976 May;91(5):607-17.@@Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB: The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol. 1996 Oct;36(10):911-22. |
| Groups | Approved; Investigational |
| Direct Classification | Diphenylmethanes |
| SMILES | CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1 |
| Pathways | Clemastine H1-Antihistamine Action |
| PharmGKB | PA164776997 |
| ChEMBL | CHEMBL1626 |
